Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company offers pharmaceuticals for the treatment of breast cancer, hypertension, ventricular arrhythmias, stage D2 metastatic carcinoma of the prostate, depression, diarrhea, infections, vasomotor symptoms of menopause, pain caused by osteoarthritis and rheumatoid arthritis, epilepsy, arrhythmia, obsessive-compulsive disorder and social anxiety disorder, ulcerative colitis, salt and fluid retention, manic episodes of bipolar disorder, ulcerative colitis, proctosigmoiditis, ocular conditions, metastatic prostate cancer, arrhythmia, migraine headache, and enterocolitis caused by staphylococcus aureus. It also provides aspirin and extended-release dipyridamole; Cholestyramine, an adjunctive therapy to diet for the reduction of elevated serum cholesterol; Ezetimibe-Simvastatin to lower high cholesterol and triglyceride levels; Fenofibrate, a peroxisome proliferator receptor alpha activator; Hydrocortisone rectal cream for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Morphine Sulfate, an oral solution for acute and chronic pain mana...
Website: anipharmaceuticals.com



Growth: Good revenue growth rate 54.1%, there is acceleration compared to average historical growth rates 46.4%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +19.7%. On average the margin is improving unsteadily. Gross margin is high, +49.1%. In the last quarter the company beat the estimated EPS, +234.3%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.14 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 9.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 118.1% higher than minimum and 17.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 5.0x by EV / Sales multiple , the company can be >100% undervalued

Insiders: For the last 3 months insiders sold company shares on $2.5 mln (-0.140% of cap.)

Key Financials (Download financials)

Ticker: ANIP
Share price, USD:  (0.0%)81.33
year average price 75.83  


year start price 60.55 2025-02-08

min close price 54.51 2025-02-25

max close price 98.81 2025-09-15

current price 81.33 2026-02-07
Common stocks: 20 074 000

Dividend Yield:  0.0%
FCF Yield LTM: 9.0%
EV / LTM EBITDA: 12.2x
EV / EBITDA annualized: 8.4x
EV / Sales: 2.4x
Margin (EBITDA LTM / Revenue): 19.7%
Fundamental value created in LTM:
Market Cap ($m): 1 633
Net Debt ($m): 358
EV (Enterprise Value): 1 991
Price to Book: 3.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-06zacks.com

Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now?

2026-01-15zacks.com

ANIP Stock Rises 7% in a Week: Here's What You Should Know

2026-01-13seekingalpha.com

ANI Pharmaceuticals, Inc. (ANIP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-13seekingalpha.com

ANI Pharmaceuticals: Strong 2025 Finish And Bullish 2026 Guidance

2026-01-13zacks.com

Strength Seen in ANI (ANIP): Can Its 10.6% Jump Turn into More Strength?

2026-01-12globenewswire.com

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities

2025-12-31zacks.com

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

2025-12-28fool.com

ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away

2025-12-22zacks.com

Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"

2025-12-22zacks.com

3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-07 2025-08-08 2024-11-08 2024-08-06 2024-05-10 2023-11-08 2023-08-09 2023-05-08 2022-11-09
acceptedDate 2025-11-07 06:57:01 2025-08-08 07:01:33 2025-02-28 07:05:36 2024-11-08 08:01:37 2024-08-06 06:57:57 2024-05-10 07:09:24 2024-02-29 07:22:42 2023-11-08 07:01:33 2023-08-09 07:00:53 2023-05-08 08:33:08 2023-03-09 16:09:01 2022-11-09 08:02:00 2022-03-15 08:30:48 2021-03-11 08:30:16
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 228M 211M 614M 148M 138M 137M 487M 132M 117M 107M 316M 84M 216M 208M
costOfRevenue 116M 75M 250M 63M 72M 64M 182M 48M 42M 38M 139M 33M 101M 87M
grossProfit 112M 137M 364M 85M 66M 74M 305M 84M 74M 69M 178M 51M 116M 121M
grossProfitRatio 0.491 0.647 0.575 0.476 0.535 0.635 0.637 0.647 0.608
researchAndDevelopmentExpenses 12M 17M 45M 10M 7M 11M 34M 11M 7M 6M 22M 8M 11M 16M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 77M 82M 250M 79M 53M 48M 162M 42M 39M 36M 124M 30M 84M 65M
otherExpenses 0 25M 69M 17M -88 000 -32 000 62M -39 000 -53 000 15M 67M 14M 60M 56M
operatingExpenses 89M 123M 364M 106M 60M 59M 258M 68M 61M 57M 213M 52M 155M 137M
costAndExpenses 205M 197M 614M 169M 133M 122M 440M 116M 103M 95M 352M 85M 256M 224M
interestIncome 0 3M 0 0 0 0 0 6M 7M 0 0 0 0 0
interestExpense 5M 8M 18M 2M 5M 5M 27M 6M 7M 8M 28M 7M 12M 9M
depreciationAndAmortization 23M 23M 68M 16M 15M 15M 60M 15M 15M 17M 60M 15M 47M 45M
ebitda 61M 39M 63M -13M 24M 30M 107M 31M 28M 27M 25M 14M 3M 28M
ebitdaratio 0.268 0.186 -0.09 0.147 0.216 0.232 0.241 0.25 0.172
operatingIncome 23M 14M 584 000 -21M 6M 15M 47M 18M 12M 10M -35M -941 000 -40M -16M
operatingIncomeRatio 0.1 0.066 -0.138 0.04 0.11 0.136 0.106 0.093 -0.011
totalOtherIncomeExpensesNet 11M -3M -23M -11M -7M 10M -27M 3M -1M -8M -27M -11M -16M -10M
incomeBeforeTax 34M 11M -22M -31M -2M 25M 20M 12M 5M 2M -63M -12M -56M -26M
incomeBeforeTaxRatio 0.148 0.05 -0.212 -0.017 0.184 0.087 0.045 0.02 -0.146
incomeTaxExpense 7M 2M -4M -7M 0 7M 1M 2M -996 000 726 000 -15M -4M -13M -3M
netIncome 24M 9M -19M -24M -2M 18M 19M 10M 6M 1M -48M -9M -43M -23M
netIncomeRatio 0.106 0.04 -0.163 -0.017 0.132 0.075 0.054 0.013 -0.103
eps 1.19 0.37 -1.04 -1.27 -0.12 0.84 0.95 0.5 0.3 0.06 -3.05 -0.53 -3.4 -1.88
epsdiluted 1.13 0.36 -1.27 -0.12 0.83 0.5 0.29 0.06 -0.53
weightedAverageShsOut 20M 20M 19M 19M 19M 19M 18M 19M 18M 16M 16M 16M 13M 12M
weightedAverageShsOutDil 21M 20M 19M 19M 19M 19M 18M 19M 18M 17M 16M 16M 13M 12M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-03-09 2022-03-15 2021-03-11
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -18M -27M -28M -12M -9M
ebit -5M 47M -35M -44M -17M
nonOperatingIncomeExcludingInterest 5M 159 000 -670 000 4M 494 000
netIncomeFromContinuingOperations -19M 19M -48M -43M -23M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -20M 17M -50M -43M -23M
epsDiluted -1.04 0.94 -3.05 -3.4 -1.88

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-07 2025-08-08 2024-11-08 2024-08-06 2024-05-10 2023-11-08 2023-08-09 2023-05-08 2022-11-09
acceptedDate 2025-11-07 06:57:01 2025-08-08 07:01:33 2025-02-28 07:05:36 2024-11-08 08:01:37 2024-08-06 06:57:57 2024-05-10 07:09:24 2024-02-29 07:22:42 2023-11-08 07:01:33 2023-08-09 07:00:53 2023-05-08 08:33:08 2023-03-09 16:09:01 2022-11-09 08:02:00 2022-03-15 08:30:48 2021-03-11 08:30:16
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 263M 218M 145M 145M 240M 229M 221M 193M 162M 68M 48M 56M 100M 8M
shortTermInvestments 0 6M 6M 8M 7M 10M 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 263M 224M 151M 153M 247M 238M 221M 193M 162M 68M 48M 56M 100M 8M
netReceivables 253M 226M 222M 196M 166M 172M 162M 179M 173M 175M 165M 140M 129M 96M
inventory 146M 138M 137M 148M 125M 114M 111M 107M 104M 104M 105M 96M 82M 61M
otherCurrentAssets 37M 15M 18M 24M 17M 16M 25M 11M 8M 7M 21M 17M 4M 0
totalCurrentAssets 698M 603M 528M 521M 555M 541M 520M 497M 459M 365M 344M 309M 322M 170M
propertyPlantEquipmentNet 64M 59M 57M 57M 52M 49M 45M 44M 44M 43M 43M 43M 53M 41M
goodwill 62M 61M 60M 60M 28M 28M 28M 28M 28M 28M 28M 28M 28M 4M
intangibleAssets 500M 520M 542M 570M 183M 196M 209M 220M 230M 239M 252M 264M 294M 189M
goodwillAndIntangibleAssets 562M 581M 602M 630M 211M 224M 237M 248M 259M 267M 280M 292M 322M 192M
longTermInvestments 0 0 0 0 7M 8M 6M 10M 9M 0 0 0 5M 5M
taxAssets 71M 92M 85M 68M 90M 88M 91M 84M 82M 81M 81M 77M 68M 52M
otherNonCurrentAssets 12M 8M 12M 11M 6M 6M 6M 6M 6M 9M 11M 17M 2M 802 000
totalNonCurrentAssets 710M 740M 756M 766M 366M 374M 385M 393M 400M 400M 416M 430M 450M 291M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 408M 1 343M 1 284M 1 287M 921M 915M 904M 890M 859M 765M 760M 739M 772M 461M
accountPayables 70M 55M 46M 61M 49M 49M 37M 34M 29M 33M 29M 19M 23M 11M
shortTermDebt 15M 13M 9M 7M 850 000 850 000 850 000 850 000 850 000 850 000 850 000 850 000 850 000 13M
taxPayables 9M 3M 7M 6M 3M 11M 8M 594 000 4M 4M 0 4M 4M 4M
deferredRevenue 0 0 0 0 3M 11M 0 75M 4M 0 0 0 87 000 80 000
otherCurrentLiabilities 176M 166M 77M 116M 88M 75M 66M 24M 89M 92M 44M 62M 44M 33M
totalCurrentLiabilities 271M 237M 194M 190M 140M 137M 145M 134M 123M 126M 99M 82M 88M 79M
longTermDebt 307M 608M 615M 618M 289M 309M 285M 285M 285M 285M 286M 286M 287M 172M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 -9M -8M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 77M 9M 8M
otherNonCurrentLiabilities 324M 36M 47M 48M 11M 16M 17M 16M 17M 14M 36M 301M 39M 14M
totalNonCurrentLiabilities 632M 645M 661M 667M 325M 326M 301M 301M 302M 300M 322M 321M 325M 187M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 0 5M 5M 0 5M 0 0 0 0 0 0
totalLiabilities 902M 881M 855M 857M 465M 463M 447M 435M 425M 426M 422M 402M 413M 265M
preferredStock 0 25M 25M 25M 25M 25M 25M 25M 25M 25M 25M 25M 25M 0
commonStock 3000 2000 2000 2000 2000 2000 2000 2000 2000 1000 1000 1000 1000 1000
retainedEarnings -51M -77M -100M -90M -65M -62M -80M -81M -90M -96M -97M -93M -48M -5M
accumulatedOtherComprehensiveIncomeLoss 3M 3M 5M 5M 8M 9M 9M 14M 14M 11M 12M 10M -3M -11M
othertotalStockholdersEquity 554M 510M 490M 463M 480M 497M 486M 400M 394M
totalStockholdersEquity 506M 462M 429M 431M 456M 452M 458M 455M 434M 339M 339M 337M 359M 196M
totalEquity 506M 462M 429M 431M 456M 452M 458M 455M 434M 339M 339M 337M 359M 196M
totalLiabilitiesAndStockholdersEquity 1 408M 1 343M 1 287M 921M 915M 890M 859M 765M 739M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 408M 1 343M 1 284M 1 287M 921M 915M 904M 890M 859M 765M 760M 739M 772M 461M
totalInvestments 0 6M 6M 8M 7M 10M 6M 10M 9M 0 0 0 5M 5M
totalDebt 323M 622M 624M 625M 310M 310M 286M 286M 286M 286M 287M 287M 287M 186M
netDebt 60M 404M 479M 480M 70M 82M 65M 93M 124M 219M 238M 230M 187M 178M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-03-09 2022-03-15 2021-03-11
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 222M 162M 165M 129M 96M
otherReceivables 0 0 0 0 0
prepaids 0 0 4M 8M 6M
totalPayables 52M 45M 29M 23M 15M
otherPayables 7M 8M 0 0 4M
accruedExpenses 55M 34M 26M 19M 17M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 0 0 0 0 0
treasuryStock -21M -10M -5M -3M -2M
additionalPaidInCapital 520M 514M 404M 388M 214M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP ANIP
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-07 2025-08-08 2024-11-08 2024-08-06 2024-05-10 2023-11-08 2023-08-09 2023-05-08 2022-11-09
acceptedDate 2025-11-07 06:57:01 2025-08-08 07:01:33 2025-02-28 07:05:36 2024-11-08 08:01:37 2024-08-06 06:57:57 2024-05-10 07:09:24 2024-02-29 07:22:42 2023-11-08 07:01:33 2023-08-09 07:00:53 2023-05-08 08:33:08 2023-03-09 16:09:01 2022-11-09 08:02:00 2022-03-15 08:30:48 2021-03-11 08:30:16
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 27M 9M -19M -22M -2M 16M 19M 10M 6M 1M -48M -9M -43M -23M
depreciationAndAmortization 23M 23M 68M 16M 15M 15M 60M 15M 15M 15M 60M 15M 47M 45M
deferredIncomeTax 19M -4M -22M -6M -2M 3M -12M -3M -910 000 773 000 -15M -2M -17M -13M
stockBasedCompensation 10M 10M 29M 7M 8M 7M 21M 5M 5M 4M 15M 4M 10M 13M
changeInWorkingCapital -18M 36M -11M 8M -5M -10M 25M 6M -7M -2M -51M -9M -84 000 -13M
accountsReceivables -27M -5M -21M 8M 6M -10M 3M -6M 2M -9M -37M 10M -6M -24M
inventory -8M -908 000 -21M -6M -12M -3M -6M -2M -669 000 2M -24M -3M 3M -3M
accountsPayables 14M 3M 479 000 -3M -1M 12M 8M 6M -4M 3M 5M -9M 10M -2M
otherWorkingCapital 4M 40M 31M 9M 2M -9M 20M 8M -4M 3M 4M -7M -8M 16M
otherNonCashItems -16M 2M 19M 9M 47M 25M 7M -731 000 2M 2M 9M 5M 5M 6M
netCashProvidedByOperatingActivities 44M 76M 64M 12M 17M 18M 119M 32M 21M 21M -31M 4M 3M 15M
investmentsInPropertyPlantAndEquipment -6M -4M -16M 9M -4M -5M -9M -5M -7M -2M -9M -10M -3M -6M
acquisitionsNet 0 0 -401M -407M 0 14M 0 0 0 0 -33 000 -33 000 -84M 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites -60 000 -3M -959 000 0 8M -3M 0 0 33 000
netCashUsedForInvestingActivites -6M -7M -399M -4M 9M -5M -7M -2M -10M
debtRepayment -2M -2M 349M -750 000 -750 000 -750 000 -750 000 -750 000 -750 000
commonStockIssued 0 0 -4M 0 3M 6M 82M 0 0
commonStockRepurchased 0 0 -11M -680 000 -1M -9M -5M -670 000 -537 000 -4M -2M -239 000 -890 000 -2M
dividendsPaid -344 000 -407 000 -406 000 -407 000 -406 000 -406 000 -407 000 -406 000 -406 000
otherFinancingActivites 9M 691 000 -57M -9M -13M 4M 0 157 000 484 000
netCashUsedProvidedByFinancingActivities 6M -2M 291M -1M -20M 4M 80M -5M -911 000
effectOfForexChangesOnCash 576 000 841 000 -470 000 -75 000 0 0 0 0 -80M 0 0 0 0 0
netChangeInCash 45M 68M -76M -95M 12M 7M 168M 31M 94M 15M -52M -7M 92M -54M
cashAtEndOfPeriod 263M 218M 145M 145M 240M 229M 221M 193M 162M 68M 53M 61M 105M 13M
cashAtBeginningOfPeriod 218M 150M 221M 240M 229M 221M 53M 162M 68M 53M 105M 68M 13M 67M
operatingCashFlow 44M 76M 64M 12M 17M 18M 119M 32M 21M 21M -31M 4M 3M 15M
capitalExpenditure -6M -7M -17M -5M -4M -5M -19M -5M -7M -2M -16M -10M -24M -68M
freeCashFlow 38M 69M 47M 7M 13M 14M 100M 28M 14M 19M -48M -6M -20M -53M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-03-09 2022-03-15 2021-03-11
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 13M -10M -7M -18M -62M
netCashProvidedByInvestingActivities -405M -19M -16M -105M -68M
netDebtIssuance 345M -3M -3M 99M -534 000
longTermNetDebtIssuance 345M -3M -3M -187M -534 000
shortTermNetDebtIssuance 0 0 0 286M 0
netStockIssuance -11M 76M -2M 94M -2M
netCommonStockIssuance -11M 76M -2M 69M -2M
commonStockIssuance 0 81M 0 70M 0
netPreferredStockIssuance 0 0 0 25M 0
netDividendsPaid -2M -2M -2M -190 000 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid -2M -2M -2M -190 000 0
otherFinancingActivities -68M -4M 1M 2M 618 000
netCashProvidedByFinancingActivities 265M 67M -5M 195M -1M
incomeTaxesPaid 19M 1M 288 000 10M 5M
interestPaid 24M 31M 21M 10M 7M

Earning call transcript

2025 q3
2025-11-07 ET (fiscal 2025 q3)
2025 q2
2025-08-08 ET (fiscal 2025 q2)
2025 q1
2025-05-09 ET (fiscal 2025 q1)
2024 q4
2025-02-28 ET (fiscal 2024 q4)
2024 q3
2024-11-08 ET (fiscal 2024 q3)
2024 q2
2024-08-09 ET (fiscal 2024 q2)
2024 q1
2024-05-10 ET (fiscal 2024 q1)
2023 q4
2024-02-29 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-09 ET (fiscal 2023 q2)
2023 q1
2023-05-08 ET (fiscal 2023 q1)
2022 q4
2023-03-09 ET (fiscal 2022 q4)
2022 q3
2022-11-09 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)
2022 q1
2022-05-10 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-11-07 06:57 ET
ANI Pharmaceuticals reported for 2025 q3
SEC form 8
2025-11-07 06:54 ET
ANI Pharmaceuticals reported for 2025 q3
SEC form 8
2025-11-07 06:54 ET
ANI Pharmaceuticals published news for 2025 q3
SEC form 8
2025-09-08 10:57 ET
ANI Pharmaceuticals published news for 2025 q2
SEC form 8
2025-09-08 10:57 ET
ANI Pharmaceuticals published news for 2025 q2
SEC form 10
2025-08-08 11:01 ET
ANI Pharmaceuticals reported for 2025 q2
SEC form 8
2025-08-08 10:56 ET
ANI Pharmaceuticals reported for 2025 q2
SEC form 8
2025-08-08 10:56 ET
ANI Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-23 20:26 ET
ANI Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-23 20:26 ET
ANI Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-23 00:00 ET
ANI Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-23 00:00 ET
ANI Pharmaceuticals published news for 2025 q2
SEC form 8
2025-06-04 11:10 ET
ANI Pharmaceuticals published news for 2025 q1
SEC form 8
2025-06-04 11:10 ET
ANI Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-20 12:05 ET
ANI Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-20 12:05 ET
ANI Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-09 10:57 ET
ANI Pharmaceuticals reported for 2025 q1
SEC form 8
2025-05-09 10:55 ET
ANI Pharmaceuticals reported for 2025 q1
SEC form 8
2025-05-09 10:55 ET
ANI Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-09 00:00 ET
ANI Pharmaceuticals reported for 2025 q1
SEC form 8
2025-03-18 11:00 ET
ANI Pharmaceuticals published news for 2024 q4
SEC form 8
2025-03-18 11:00 ET
ANI Pharmaceuticals published news for 2024 q4
SEC form 8
2025-03-14 20:10 ET
ANI Pharmaceuticals published news for 2024 q4
SEC form 8
2025-03-14 20:10 ET
ANI Pharmaceuticals published news for 2024 q4
SEC form 8
2025-03-11 00:00 ET
ANI Pharmaceuticals published news for 2024 q4
SEC form 8
2025-03-11 00:00 ET
ANI Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-28 12:05 ET
ANI Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-28 00:00 ET
ANI Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-28 00:00 ET
ANI Pharmaceuticals reported for 2024 q4
SEC form 8
2025-02-28 00:00 ET
ANI Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-05 00:00 ET
ANI Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-05 00:00 ET
ANI Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
ANI Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
ANI Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
ANI Pharmaceuticals published news for 2024 q4
SEC form 8
2024-11-20 00:00 ET
ANI Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-20 00:00 ET
ANI Pharmaceuticals published news for 2024 q3
SEC form 10
2024-11-08 08:01 ET
ANI Pharmaceuticals reported for 2024 q3
SEC form 8
2024-11-08 06:55 ET
ANI Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-08 06:55 ET
ANI Pharmaceuticals reported for 2024 q3
SEC form 10
2024-08-06 06:57 ET
ANI Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-06 06:53 ET
ANI Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-06 06:53 ET
ANI Pharmaceuticals published news for 2024 q2
SEC form 10
2024-08-06 00:00 ET
ANI Pharmaceuticals published news for 2024 q2
SEC form 8
2024-06-05 00:00 ET
ANI Pharmaceuticals published news for 2024 q1
SEC form 8
2024-06-05 00:00 ET
ANI Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-14 00:00 ET
ANI Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-14 00:00 ET
ANI Pharmaceuticals published news for 2024 q1
SEC form 10
2024-05-10 00:00 ET
ANI Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-10 00:00 ET
ANI Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-10 00:00 ET
ANI Pharmaceuticals reported for 2024 q1
SEC form 8
2024-04-17 00:00 ET
ANI Pharmaceuticals published news for 2024 q1
SEC form 8
2024-04-17 00:00 ET
ANI Pharmaceuticals published news for 2024 q1
SEC form 8
2024-03-12 00:00 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 8
2024-03-12 00:00 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-29 07:22 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-29 06:58 ET
ANI Pharmaceuticals reported for 2023 q4
SEC form 8
2024-02-29 06:58 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-29 00:00 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-08 00:00 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-08 00:00 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
ANI Pharmaceuticals published news for 2023 q4
SEC form 8
2023-11-15 00:00 ET
ANI Pharmaceuticals published news for 2023 q3
SEC form 10
2023-11-08 07:01 ET
ANI Pharmaceuticals reported for 2023 q3
SEC form 8
2023-11-08 06:57 ET
ANI Pharmaceuticals published news for 2023 q3
SEC form 8
2023-09-25 00:00 ET
ANI Pharmaceuticals published news for 2023 q2
SEC form 8
2023-09-12 00:00 ET
ANI Pharmaceuticals published news for 2023 q2
SEC form 8
2023-09-07 00:00 ET
ANI Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-30 00:00 ET
ANI Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-09 07:00 ET
ANI Pharmaceuticals reported for 2023 q2
SEC form 6
2023-08-09 06:56 ET
ANI Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-09 00:00 ET
ANI Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-09 00:00 ET
ANI Pharmaceuticals published news for 2023 q2
SEC form 8
2023-06-09 00:00 ET
ANI Pharmaceuticals published news for 2023 q1
SEC form 6
2023-06-08 20:00 ET
ANI Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
ANI Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
ANI Pharmaceuticals published news for 2023 q1
SEC form 10
2023-03-09 00:00 ET
ANI Pharmaceuticals reported for 2022 q4
SEC form 8
2023-03-09 00:00 ET
ANI Pharmaceuticals reported for 2022 q4
SEC form 8
2022-11-09 00:00 ET
ANI Pharmaceuticals published news for 2022 q3
SEC form 8
2022-11-09 00:00 ET
ANI Pharmaceuticals reported for 2022 q3
SEC form 10
2022-11-09 00:00 ET
ANI Pharmaceuticals reported for 2022 q3
SEC form 8
2022-08-08 00:00 ET
ANI Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-08 00:00 ET
ANI Pharmaceuticals reported for 2022 q2
SEC form 8
2022-05-10 00:00 ET
ANI Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-10 00:00 ET
ANI Pharmaceuticals reported for 2022 q1
SEC form 8
2022-03-15 00:00 ET
ANI Pharmaceuticals published news for 2021 q4
SEC form 10
2022-03-15 00:00 ET
ANI Pharmaceuticals published news for 2021 q4
SEC form 8
2021-11-01 00:00 ET
ANI Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-01 00:00 ET
ANI Pharmaceuticals published news for 2021 q3
SEC form 10
2021-08-06 00:00 ET
ANI Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-06 00:00 ET
ANI Pharmaceuticals published news for 2021 q2
SEC form 10
2021-05-07 00:00 ET
ANI Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-07 00:00 ET
ANI Pharmaceuticals published news for 2021 q1